Aurora Cannabis Launches First Domestically Grown Medical Cannabis Brand in Germany Under New Cultivation License

$ACB
Medicinal Chemicals and Botanical Products
Health Care
Get the next $ACB alert in real time by email

NASDAQ | TSX: ACB

Investment in the region continues with the launch of IndiMed, the company's first locally grown brand in Germany

EDMONTON, AB, Jan. 23, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, announces today the launch of the company's first German-cultivated medical cannabis product, under the brand IndiMed. Manufactured at Aurora's leading EU-GMP facility in Leuna, Germany, the new brand offers a supply of high-quality, locally grown and sold, medical cannabis for the country's expanding patient base.

"Aurora is proud to deliver to the rapidly growing German market our first domestically produced medical cannabis product – a significant step forward since Germany's move to decriminalize cannabis earlier this year," says Michael Simon, President, Aurora Europe (Interim). "As one of three facilities licensed to cultivate in Germany, we are uniquely positioned to offer domestic product from our EU-GMP facility in Leuna, Germany, which operates within Aurora's global manufacturing network. It is through our expertise in cultivation and deep commitment to science and innovation that we introduce IndiMed to the German patients."

The premium product launching from the IndiMed brand is Island Sweet Skunk, dried flower, sativa, 20% THC, <1 % CBD. Product is expected to be available on January 27. IndiMed is cultivated under GACP and EU-GMP guidelines to ensure pharmaceutical-grade quality. The flowers are harvested by hand, dried under controlled conditions, and tested in the state-of-the-art laboratory for purity and active ingredient content.

Aurora leads the global medical cannabis industry with unmatched expertise, driving innovation and progress. Its steadfast commitment to growth in the dynamic German market cements its position as the industry's unrivaled leader.

Aurora's expertise in navigating complex European regulatory frameworks and manufacturing high-quality medical cannabis positions the company as the preferred leader to drive progress in the German market with confidence. By continually setting new global benchmarks, Aurora reinforces its status as the world's largest medical cannabis company operating in nationally legal markets.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at   www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".                             

Forward Looking Information   

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the launch of the Company's first German-cultivated medical cannabis product under the brand IndiMed, the timing for availability of that product in the German market, the Company's market leadership and status as the world's largest medical cannabis company operating in nationally legal markets, and the Company's ability to drive progress in the German market.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-launches-first-domestically-grown-medical-cannabis-brand-in-germany-under-new-cultivation-license-302357848.html

SOURCE Aurora Cannabis Inc.

Get the next $ACB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ACB

DatePrice TargetRatingAnalyst
12/11/2024Buy
TD Cowen
2/9/2024Hold → Buy
Canaccord Genuity
9/21/2022Sell → Hold
Canaccord Genuity
6/24/2022Neutral → Overweight
Cantor Fitzgerald
6/6/2022Sell → Hold
Stifel
11/10/2021$9.60 → $10.75Neutral
Cantor Fitzgerald
10/28/2021$9.50 → $9.60Neutral
Cantor Fitzgerald
10/5/2021$8.30 → $9.50Neutral
Cantor Fitzgerald
More analyst ratings

$ACB
Press Releases

Fastest customizable press release news feed in the world

See more
  • Aurora Cannabis Expands Medical Cannabis Pastille Offerings in Australia

    Canada's Leading Medical Cannabis Company Broadens Innovative Product Portfolio to Growing Market in Australia EDMONTON, AB, Feb. 20, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, has announced today the company's extended pastille offerings in Australia. This expansion marks another meaningful step in Aurora's deep commitment to offering patients a diverse range of high-quality, premium medical cannabis products to meet their various needs and interests. "Expanding our portfolio of medical cannabi

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
  • Breaking Down Barriers: Aurora Cannabis Eases Patient Access to High Quality Medical Cannabis Products in Australia

     NASDAQ | TSX: ACB Largest Global Medical Cannabis Company Operating in Nationally Regulated Markets, Aurora Removes Concession Card Requirements to Access IndiMed Products in Australia EDMONTON, AB, Feb. 14, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, in conjunction with MedReleaf Australia, recently removed the concession card requirement for patients to access medical cannabis products under the Company's IndiMed brand. By removing this eligibility barrier, any patient in Australia can now be prescribed IndiMed products, providing greater patient access to high quality medical can

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
  • Aurora Cannabis Announces Supply Agreement with SNDL

    NASDAQ | TSX: ACB Agreement Complements Existing Relationship Focused on the Supply of Premium Cannabis  EDMONTON, AB, February 6, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB) –the Canadian based leading global medical cannabis company, is pleased to announce a strategic supply agreement (the "Agreement") with SNDL Inc. ("SNDL"), a Canadian licensed producer and vertically integrated cannabis enterprise. Under this Agreement, SNDL is expected to supply Aurora with premium cannabis flower product grown at SNDL's indoor facility in

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

$ACB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ACB
SEC Filings

See more

$ACB
Leadership Updates

Live Leadership Updates

See more
  • Aurora CEO Miguel Martin takes on additional role as Executive Chairman of Board of Directors

    NASDAQ | TSX: ACB Outgoing Chairman Ron Funk appointed Lead Independent Director, as part of Board leadership transition EDMONTON, AB, Sept. 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced the appointments of CEO Miguel Martin to the additional role of Executive Chairman and outgoing Chairman Ron Funk as Lead Independent Director. Both appointments follow unanimous votes by Aurora's Board and are effective immediately. Mr. Martin has served as Chief Executiv

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
  • Aurora Cannabis Announces Results of 2024 Annual General and Special Meeting

    NASDAQ | TSX: ACB EDMONTON, AB, Aug. 12, 2024 /PRNewswire/ -  Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held Friday August 9, 2024 by virtual webcast. The total number of shares represented by shareholders present in person (virtually) and by proxy at the Meeting was 14,855,306, representing 27.23% of Aurora's issued and outstanding common shares as of the record date. All of

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
  • Aurora Cannabis Announces Appointment of New Director

     NASDAQ | TSX: ACB  Newly created directorship to be filled by Rajesh Uttamchandani EDMONTON, AB, May 15, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today the appointment of Rajesh Uttamchandani to the Company's Board of Directors (the "Board"), effective today. Mr. Uttamchandani joins the Board with notable expertise in strategy development, innovation, human capital and governance. His impressive career is characterized by executive level roles with leadin

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

$ACB
Financials

Live finance-specific insights

See more
  • Aurora Cannabis Announces Fiscal 2025 Third Quarter Results

    NASDAQ | TSX: ACB Reports Total Net Revenue1 of $88.2 Million, up 37% YoY, Including Record Net Revenue1 of $68.1 Million in Global Medical Cannabis, up 51% YoYGenerates Record Net Income of $31.2 Million, up 282% YoY, and Record Adjusted EBITDA1 of $23.1 Million, up 316% YoYAchieves Target of Positive Free Cash Flow1 in Q3, Generating $27.4 Million of Free Cash Flow1Maintains Strong Balance Sheet with $180 Million of Cash and Debt-Free Cannabis Business2EDMONTON, AB, Feb. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third qu

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
  • Aurora Cannabis to Host Third Quarter 2025 Investor Conference Call

    NASDAQ | TSX: ACB EDMONTON, AB, Jan. 22, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its third quarter 2025 on Wednesday, February 5, 2025 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the third quarter 2025 before the opening of markets that same day. Conference Call Details DATE: Wednesday, February 5, 2025 TIME: 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time WEBCAST: Click Here Miguel Martin, Executive Chairman and Chief Executive Officer,

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
  • Aurora Cannabis Announces Fiscal 2025 Second Quarter Results

    NASDAQ | TSX: ACB Record Adjusted EBITDA1 of $10.1 Million, a YoY increase of 210%Quarterly Net Revenue1 up 29% YoY to $81.1 Million, with 41% growth in Global Medical CannabisRe-Affirms Target of Positive Free Cash Flow1 in the Quarter Ending December 31, 2024Maintains Strong Balance Sheet with ~$152 Million of Cash and a Debt-Free Cannabis Business2EDMONTON, AB, Nov. 6, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter fiscal 2025.

    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

$ACB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more